Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in Anti-JCV Antibody Negative Patients with MS

Marketing Applications Supported by Risk Stratification Data WESTON, Mass. & DUBLIN--(Healthcare Sales & Marketing Network)--Today Biogen Idec (BIIB) and Elan Corporation, plc (ELN) announced that they have submitted applications to the U.S. Food and Dr... Biopharmaceuticals, NeurologyElan Corp, Biogen Idec, TYSABRI, natalizumab, multiple sclerosis, JC virus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news